GSB Wealth Management’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-1,037
Closed -$335K 236
2025
Q3
$335K Buy
1,037
+160
+18% +$49.8K 0.08% 170
2025
Q2
$341K Sell
877
-3
-0.3% -$1.21K 0.08% 176
2025
Q1
$383K Sell
880
-9
-1% -$3.61K 0.1% 154
2024
Q4
$328K Sell
889
-58
-6% -$24.3K 0.08% 172
2024
Q3
$493K Buy
947
+1
+0.1% +$534 0.13% 143
2024
Q2
$513K Buy
946
+1
+0.1% +$529 0.14% 143
2024
Q1
$490K Buy
945
+2
+0.2% +$995 0.14% 143
2023
Q4
$445K Buy
943
+1
+0.1% +$462 0.14% 139
2023
Q3
$410K Buy
942
+9
+1% +$4.08K 0.14% 138
2023
Q2
$415K Buy
933
+1
+0.1% +$461 0.13% 142
2023
Q1
$428K Buy
932
+1
+0.1% +$476 0.14% 149
2022
Q4
$477K Sell
931
-8
-0.9% -$4.06K 0.17% 140
2022
Q3
$427K Buy
939
+1
+0.1% +$478 0.15% 151
2022
Q2
$453K Sell
938
-107
-10% -$52.9K 0.15% 151
2022
Q1
$513K Buy
1,045
+1
+0.1% +$457 0.15% 158
2021
Q4
$484K Buy
+1,044
New +$439K 0.14% 160
2021
Q3
Sell
-803
Closed -$306K 174
2021
Q2
$306K Buy
803
+1
+0.1% +$382 0.1% 184
2021
Q1
$288K Buy
+802
New +$258K 0.1% 173

Other funds holding ELV

GSB Wealth Management's ELV Position: Q4 2025 in Review

GSB Wealth Management sold out of Elevance Health (ELV) in Q4 2025, closing a stake of 1,037 shares — an estimated $335K sold.

GSB Wealth Management first reported a position in ELV in Q1 2021 and held it in 18 quarters. The position peaked at $513K in Q1 2022. 1,553 funds tracked by Wall St. Rank hold ELV as of Q4 2025.

  • GSB Wealth Management reported no remaining Elevance Health position as of Q4 2025 after selling out during the quarter.
  • GSB Wealth Management sold 1,037 Elevance Health shares in Q4 2025, an estimated $335K.
  • GSB Wealth Management first reported a position in Elevance Health in Q1 2021 and held it in 18 quarters.
  • GSB Wealth Management's Elevance Health position peaked at $513K in Q1 2022.
  • 1,553 funds tracked by Wall St. Rank held Elevance Health as of Q4 2025.

Based on GSB Wealth Management's 13F filing for Q4 2025, filed 5 Feb 2026.